<p>根據最近向美國證券交易委員會提交的 13F 文件，Nordea Investment Management AB 在 2023 年第二季度將其在 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）的股份增加了 1.1%。該基金在本季度購買了額外的 53,733 股後，持有該公司 4,904,076 股股票。在最近的報告期結束時，Nordea Investment Management AB 持有的 Organon &amp; Co.的股份約佔 1.89%，價值 48,281,000 美元。</p>
<p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<ul>
<li>道瓊斯最熱門的股票默克準備發佈第四季度財報</li>
</ul>
<p>其他幾家機構投資者最近也買賣了 OGN 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Organon &amp; Co.的持倉增加了 870.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 1,010,789 股該公司的股票，價值 15,051,000 美元，此前在上個季度購買了 906,675 股。馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）在第一季度將其在 Organon &amp; Co.的持倉增加了 8.3%。馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）現在擁有 10,715,445 股該公司的股票，價值 159,553,000 美元，此前在上個季度購買了 820,378 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在 Organon &amp; Co.的持倉增加了 126.4%。高盛集團（Goldman Sachs Group Inc.）現在擁有 1,435,198 股該公司的股票，價值 21,370,000 美元，此前在此期間收購了 801,307 股。Gotham Asset Management LLC 在第一季度將其在 Organon &amp; Co.的持倉增加了 74.3%。Gotham Asset Management LLC 現在擁有 1,400,250 股該公司的股票，價值 20,850,000 美元，此前在此期間收購了 596,936 股。最後，Nuveen LLC 在第一季度購買了 Organon &amp; Co.的新頭寸，價值約為 8,773,000 美元。77.43% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Organon &amp; Co. 價格表現</h2>
<p>OGN 在週五開盤價為 9.28 美元。該公司的債務與股本比率為 11.98，速動比率為 1.13，流動比率為 1.65。該股票的市值為 24.1 億美元，市盈率為 3.45，市盈增長比率為 0.84，貝塔值為 0.63。該公司的 50 日簡單移動平均線為 9.93 美元，200 日簡單移動平均線為 10.02 美元。Organon &amp; Co.的 52 周低點為 8.01 美元，52 周高點為 19.05 美元。</p>
<ul>
<li>Lululemon Athletica 因進入標準普爾 500 指數而創下新高</li>
</ul>
<p>Organon &amp; Co.（紐約證券交易所代碼：OGN - 獲取免費報告）最近於 8 月 5 日星期二發佈了季度財報。該公司報告本季度每股收益為 1.00 美元，超出市場共識預期的 0.94 美元，超出幅度為 0.06 美元。Organon &amp; Co.的淨利潤率為 11.15%，股本回報率為 163.88%。該公司本季度的收入為 15.9 億美元，而分析師的預期為 15.5 億美元。在去年同期，該公司每股收益為 1.12 美元。該公司的季度收入同比下降了 0.8%。Organon &amp; Co.已設定 2025 財年的每股收益指導。整體來看，分析師預測 Organon &amp; Co.在當前年度的每股收益為 3.68 美元。</p>
<h2>Organon &amp; Co. 股息公告</h2>
<p>該公司最近還披露了季度股息，該股息於 9 月 11 日星期四支付。8 月 15 日星期五的股東獲得了 0.02 美元的股息。這代表着每年 0.08 美元的股息和 0.9% 的股息收益率。除息日期為 8 月 15 日星期五。Organon &amp; Co.的股息支付比率為 2.97%。</p>
<h2>華爾街分析師觀點</h2>
<p>另外，Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Organon &amp; Co.股票的 “賣出（d+）” 評級。一位投資分析師對該股票給予了強烈買入評級，兩位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Organon &amp; Co.目前的平均評級為 “適度買入”，共識目標價為 17.33 美元。</p>
<p><strong>查看我們關於 Organon &amp; Co.的最新研究報告</strong></p>
<h2>Organon &amp; Co. 公司簡介</h2>
<p>（免費報告）</p>
<p>Organon &amp; Co.是一家基於科學的全球製藥公司，通過一系列處方療法在女性健康、生物仿製藥和成熟品牌領域開發和提供創新的健康解決方案。該公司成立於 2020 年 3 月 11 日，總部位於新澤西州澤西市。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Organon &amp; Co.</li>
<li>複利及其在投資中的重要性</li>
<li>強生的併購戰略才是投資者真正關注的故事</li>
<li>10 只最佳航空公司股票</li>
<li>特斯拉：一些分析師預測將下跌 30%——是時候恐慌了嗎？</li>
<li>10 美元以下的最佳股票</li>
<li>對沖基金對美元的態度轉變——這三隻股票的買入信號？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Organon &amp; Co.嗎？</h2>
<p>在考慮投資 Organon &amp; Co.之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場關注之前購買……而 Organon &amp; Co.並不在名單上。</p>
<p>雖然 Organon &amp; Co.目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Nordea Investment Management AB 在第二季度將其在 Organon & Co. (NYSE: OGN) 的持股比例增加了 1.1%，目前持有 4,904,076 股，價值 4828 萬美元。其他機構投資者也顯著增加了他們的持倉。Organon 報告第二季度每股收益為 1.00 美元，超出預期，收入為 15.9 億美元。該公司的市值為 24.1 億美元，股息收益率為 0.9%。分析師對該股票的評級不一，平均評級為 “適度買入”，目標價格為 17.33 美元</p>

<p>Nordea Investment Management AB boosted its position in shares of Organon &amp; Co. (NYSE:OGN - Free Report) by 1.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,904,076 shares of the company's stock after purchasing an additional 53,733 shares during the quarter. Nordea Investment Management AB owned about 1.89% of Organon &amp; Co. worth $48,281,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據最近向美國證券交易委員會提交的 13F 文件，Nordea Investment Management AB 在 2023 年第二季度將其在 Organon &amp; Co.（紐約證券交易所代碼：OGN - 免費報告）的股份增加了 1.1%。該基金在本季度購買了額外的 53,733 股後，持有該公司 4,904,076 股股票。在最近的報告期結束時，Nordea Investment Management AB 持有的 Organon &amp; Co.的股份約佔 1.89%，價值 48,281,000 美元。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>道瓊斯最熱門的股票默克準備發佈第四季度財報</li>
</ul>
</div><p>Several other institutional investors also recently bought and sold shares of OGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Organon &amp; Co. by 870.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company's stock valued at $15,051,000 after purchasing an additional 906,675 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Organon &amp; Co. by 8.3% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 10,715,445 shares of the company's stock valued at $159,553,000 after purchasing an additional 820,378 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Organon &amp; Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company's stock valued at $21,370,000 after acquiring an additional 801,307 shares during the period. Gotham Asset Management LLC lifted its stake in Organon &amp; Co. by 74.3% during the 1st quarter. Gotham Asset Management LLC now owns 1,400,250 shares of the company's stock valued at $20,850,000 after acquiring an additional 596,936 shares during the period. Finally, Nuveen LLC bought a new position in Organon &amp; Co. during the 1st quarter valued at about $8,773,000. 77.43% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也買賣了 OGN 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度將其在 Organon &amp; Co.的持倉增加了 870.8%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 1,010,789 股該公司的股票，價值 15,051,000 美元，此前在上個季度購買了 906,675 股。馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）在第一季度將其在 Organon &amp; Co.的持倉增加了 8.3%。馬薩諸塞金融服務公司（Massachusetts Financial Services Co. MA）現在擁有 10,715,445 股該公司的股票，價值 159,553,000 美元，此前在上個季度購買了 820,378 股。高盛集團（Goldman Sachs Group Inc.）在第一季度將其在 Organon &amp; Co.的持倉增加了 126.4%。高盛集團（Goldman Sachs Group Inc.）現在擁有 1,435,198 股該公司的股票，價值 21,370,000 美元，此前在此期間收購了 801,307 股。Gotham Asset Management LLC 在第一季度將其在 Organon &amp; Co.的持倉增加了 74.3%。Gotham Asset Management LLC 現在擁有 1,400,250 股該公司的股票，價值 20,850,000 美元，此前在此期間收購了 596,936 股。最後，Nuveen LLC 在第一季度購買了 Organon &amp; Co.的新頭寸，價值約為 8,773,000 美元。77.43% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Organon &amp; Co. Price Performance</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 價格表現</h2>
</div><p>OGN opened at $9.28 on Friday. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a market capitalization of $2.41 billion, a P/E ratio of 3.45, a P/E/G ratio of 0.84 and a beta of 0.63. The company's 50-day simple moving average is $9.93 and its two-hundred day simple moving average is $10.02. Organon &amp; Co. has a 52-week low of $8.01 and a 52-week high of $19.05.</p>
<div class="lb-trans"><p>OGN 在週五開盤價為 9.28 美元。該公司的債務與股本比率為 11.98，速動比率為 1.13，流動比率為 1.65。該股票的市值為 24.1 億美元，市盈率為 3.45，市盈增長比率為 0.84，貝塔值為 0.63。該公司的 50 日簡單移動平均線為 9.93 美元，200 日簡單移動平均線為 10.02 美元。Organon &amp; Co.的 52 周低點為 8.01 美元，52 周高點為 19.05 美元。</p>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 因進入標準普爾 500 指數而創下新高</li>
</ul>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon &amp; Co. had a net margin of 11.15% and a return on equity of 163.88%. The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. During the same quarter in the prior year, the business earned $1.12 EPS. The business's quarterly revenue was down .8% on a year-over-year basis. Organon &amp; Co. has set its FY 2025 guidance at EPS. As a group, analysts predict that Organon &amp; Co. will post 3.68 EPS for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co.（紐約證券交易所代碼：OGN - 獲取免費報告）最近於 8 月 5 日星期二發佈了季度財報。該公司報告本季度每股收益為 1.00 美元，超出市場共識預期的 0.94 美元，超出幅度為 0.06 美元。Organon &amp; Co.的淨利潤率為 11.15%，股本回報率為 163.88%。該公司本季度的收入為 15.9 億美元，而分析師的預期為 15.5 億美元。在去年同期，該公司每股收益為 1.12 美元。該公司的季度收入同比下降了 0.8%。Organon &amp; Co.已設定 2025 財年的每股收益指導。整體來看，分析師預測 Organon &amp; Co.在當前年度的每股收益為 3.68 美元。</p>
</div><h2>Organon &amp; Co. Dividend Announcement</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股息公告</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Stockholders of record on Friday, August 15th were paid a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 15th. Organon &amp; Co.'s dividend payout ratio is 2.97%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，該股息於 9 月 11 日星期四支付。8 月 15 日星期五的股東獲得了 0.02 美元的股息。這代表着每年 0.08 美元的股息和 0.9% 的股息收益率。除息日期為 8 月 15 日星期五。Organon &amp; Co.的股息支付比率為 2.97%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Organon &amp; Co. presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $17.33.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日星期三的研究報告中重申了對 Organon &amp; Co.股票的 “賣出（d+）” 評級。一位投資分析師對該股票給予了強烈買入評級，兩位給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Organon &amp; Co.目前的平均評級為 “適度買入”，共識目標價為 17.33 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Organon &amp; Co.</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Organon &amp; Co.的最新研究報告</strong></p>
</div><h2>Organon &amp; Co. Company Profile</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Organon &amp; Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.</p>
<div class="lb-trans"><p>Organon &amp; Co.是一家基於科學的全球製藥公司，通過一系列處方療法在女性健康、生物仿製藥和成熟品牌領域開發和提供創新的健康解決方案。該公司成立於 2020 年 3 月 11 日，總部位於新澤西州澤西市。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Best Stocks Under $10.00</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Organon &amp; Co.</li>
<li>複利及其在投資中的重要性</li>
<li>強生的併購戰略才是投資者真正關注的故事</li>
<li>10 只最佳航空公司股票</li>
<li>特斯拉：一些分析師預測將下跌 30%——是時候恐慌了嗎？</li>
<li>10 美元以下的最佳股票</li>
<li>對沖基金對美元的態度轉變——這三隻股票的買入信號？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=OGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Organon &amp; Co.嗎？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Organon &amp; Co.之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場關注之前購買……而 Organon &amp; Co.並不在名單上。</p>
</div><p>While Organon &amp; Co. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Organon &amp; Co.目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Nordea Investment Management AB 增加了在 Organon & Co. $OGN 的持股